reversed-phase HPLC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-01. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved for therapeutic use | No marketing authorisation from major agencies |
| Legal classification | Varies by jurisdiction | Prescription-only or controlled in several countries |
| Common synonyms | Melanotan II; MT-II | Also referenced by catalogue codes |
| Typical analytical method | Reverse-phase HPLC | Often paired with mass spectrometry |
| Primary literature focus | Receptor pharmacology | Pigmentation and melanocortin signalling |
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
The ONS publishes its latest forecast of UK population, suggesting that the number of people in the UK could rise from 67 to 73.7 million by 2036, driven by strong immigration. 31 January Post-Brexit controls on food, plant and animal imports to Britain from the EU come into force. 2024 Northern Ireland Executive Formation: Details of a deal between the UK government and the Democratic Unionist Party (DUP) to restore devolution in Northern Ireland are published. Nine people, including three police officers, are taken to hospital following an attack using what is described as a "corrosive substance" on a car in Clapham, south west London. The suspect is named as Abdul Shakoor Ezedi, a 35-year-old man from the "Newcastle area".
In some organisms, the enzyme can use alternative keto acids instead of α-ketoglutaric acid. It has been found in pea, and the genes coding for the enzyme have been studied in Bacillus sphaericus. This enzyme belongs to the family of transferases, specifically the transaminases, which transfer nitrogenous groups. The systematic name of this enzyme class is D-alanine:2-oxoglutarate aminotransferase. Other names in common use include D-aspartate transaminase, D-alanine aminotransferase, D-aspartic aminotransferase, D-alanine-D-glutamate transaminase, D-alanine transaminase, and D-amino acid aminotransferase. This enzyme participates in 6 metabolic pathways: lysine degradation, arginine and proline metabolism, phenylalanine metabolism, D-arginine and D-ornithine metabolism, D-alanine metabolism, and peptidoglycan biosynthesis. It employs one cofactor, pyridoxal phosphate.
== Early autosomal research == Before the discovery of mtDNA variation and Y-chromosomal variation in the 1980s and 1990s, respectively, it was not possible to distinguish male from female effects in population genetics. Instead, researchers had to rely on autosomal variation, starting with the first population genetic study using blood groups by Ludwik Hirszfeld in 1919. Later other genetic polymorphisms were used, for example polymorphisms of proteins of the blood plasma, polymorphisms of human lymphocyte antigens or polymorphisms of immunoglobulins. On this basis, correlations between languages and genetic variation occasionally were proposed, but sex-specific questions could not be addressed until the 1990s, when both mtDNA and Y-chromosomal variation in humans became available for study.
Sources: en.wikipedia.org
Agricultural and tropical regions report more snakebites than anywhere else. In the United States, those bitten are typically male and between 17 and 27 years of age. Children and the elderly are the most likely to die.
=== Middle East === Palestine: Palestinian Authority president Mahmoud Abbas stated "We will not allow the rights of our people [...] to be infringed on" and affirmed that Gaza is "an integral part of the State of Palestine." Palestinian foreign minister Varsen Aghabekian reiterated the Palestinian Authority's de jure authority over the Gaza Strip, rejected the plan as "unacceptable", and called on other Western countries to do the same. Hamas: Hamas condemned Trump's plan and warned that such a plan would "put oil on the fire in the region". Houthis: Yemeni Houthi authorities released a statement saying that the plan represented "American arrogance" that will subsume all if it is met with "submission from the Arabs". Iran: Iran stated that "Iran does not agree with any displacement of Palestinians and has communicated this through various channels" Saudi Arabia: Saudi Arabia rejected the plan and said that it would "continue its relentless efforts to establish an independent Palestinian state with East Jerusalem as its capital, and will not establish diplomatic relations with Israel without that".
Biuret ( BYUR-ret) is a chemical compound with the chemical formula HN(CONH2)2. It is a white solid that is soluble in hot water. A variety of organic derivatives are known. The term "biuret" also describes a family of organic compounds with the chemical formula R1R2N−C(=O)−N(R3)−C(=O)−NR4R5, where R1, R2, R3, R4 and R5 are hydrogen, organyl or other groups. Also known as carbamylurea, it results from the condensation of two equivalents of urea. It is a common undesirable impurity in urea-based fertilizers, as biuret is toxic to plants.
== Differential diagnosis == Other disorders that may be accompanied by chorea include benign hereditary chorea, bilateral striatal necrosis, abetalipoproteinemia, ataxia–telangiectasia, biotin-thiamine-responsive basal ganglia disease (BTBGD), Fahr disease, familial dyskinesia–facial myokymia (Bird–Raskind syndrome) due to an ADCY5 gene mutation, glutaric aciduria, Lesch–Nyhan syndrome, mitochondrial disorders, Huntington's disease, Wilson disease, hyperthyroidism, lupus erythematosus, pregnancy (chorea gravidarum), drug intoxication and side effects of certain anticonvulsants (e.g. phenytoin) or psychotropic agents. Although some of these can similarly present in an acute way, there will typically be other neurological signs (such as ataxia or cognitive impairment), or other disease manifestations, or positive family history, which will help distinguish between them.
Sources: en.wikipedia.org
== Further reading == Jackie Y. Ying (2001). Nanostructured Materials. Academic Press. pp. 5–. ISBN 978-0-12-744451-2. Nanoparticles Used in Solar Energy Conversion (ScienceDaily). "Nanoparticles: An occupational hygiene review" Archived 24 September 2015 at the Wayback Machine by RJ Aitken and others. Health and Safety Executive Research Report 274/2004 "EMERGNANO: A review of completed and near completed environment, health and safety research on nanomaterials and nanotechnology" by RJ Aitken and others. High transmission Tandem DMA for nanoparticle studies by SEADM, 2014.
=== 19 kDa Protein === This catalytic component of OpLuc has 196 amino acids with one cysteine in the carboxyl terminus and is distinct from proteins found in other luciferases. The protein is made up of two domains with repetitive sequencing of Ia-c and Ila-d in the peptide chain. It is thought to be the protein to cause the bioluminescent reaction of O.gracilirostris, but functions ineffectively without its larger, subunit counterpart. Although the crystal structure of OpLec has yet to be completely analyzed and mapped, 19 kDa experimentally expressed in mammalian cells (regarded as KAZ). The protein was isolated and mutated to catalyze a bright and sustained luminescent reaction to create an engineered luciferase, NanoLuc (NLuc), and a coelenterazine analogue (furimazine) to be used as a cellular reporter. Additional substrates with increased aqueous solubility (hydrofurimazine, fluorofurimazine, cephalofurimazine, and cephalofurimazine-9) were later developed.
substituent An atom or a group of atoms which substitutes or replaces another atom or group of atoms within a larger molecule as the product of a chemical reaction, thereby becoming a moiety of the newly formed compound, generally without causing any significant change to other parts of the same molecule. For example, a hydroxyl group may be substituted for any of the hydrogen atoms in benzene to form phenol. See also side chain and functional group.
Sources: en.wikipedia.org
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.
Much of the evidence comes from case reports and accounts of unregulated use rather than controlled trials. Differences in product purity and dosing add further variability.
Laboratory work focuses on receptor binding and cellular signalling. Observational reports document outcomes after use, and analytical chemists examine samples to assess content and purity.
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.